Synergy Pharmaceuticals Inc SGYP Financial and Strategic SWOT Analysis Review [Updated: 13062017] Prices from USD $125

21:12 EDT 22 Jun 2017 | BioPortfolio Reports

Synergy Pharmaceuticals Inc SGYP Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Synergy Pharmaceuticals Inc Synergy Pharma develops therapies for gastrointestinal GI diseases. The company's portfolio includes Trulance plecanatide indicated for the treatment of chronic idiopathic constipation CIC in adults. It employs its proprietary GI platform based on uroguanylin, a naturally occurring human GI peptide that promotes normal bowel function. Synergy Pharma's therapeutic focus spans the areas of chronic idiopathic constipation CIC, opioid induced constipation OIC, irritable bowel syndrome with constipation IBSC and ulcerative colitis UC. The company's pipeline includes dolcanatide SP333, an investigational candidate targeted at the treatment of OIC and UC. Synergy Pharma is headquartered in New York, the US.

Synergy Pharmaceuticals Inc Key Recent Developments

May 10,2017: Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update
Apr 17,2017: Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer
Mar 01,2017: Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update
Nov 09,2016: Synergy Pharmaceuticals Reports Third Quarter 2016 Financial Results and Business Update
Aug 08,2016: Synergy Pharmaceuticals Reports Second Quarter 2016 Financial Results and Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Synergy Pharmaceuticals Inc SGYP Financial and Strategic SWOT Analysis Review [Updated: 13062017] Prices from USD $125


More From BioPortfolio on "Synergy Pharmaceuticals Inc SGYP Financial and Strategic SWOT Analysis Review [Updated: 13062017] Prices from USD $125"

Quick Search


Relevant Topic

Irritable Bowel Syndrome IBS
Irritable bowel syndrome (IBS) is a common but poorly understood chronic (long-term) condition where the normal functions of the bowel are disrupted. Symptoms of IBS include abdominal pain or discomfort, changes in bowel habits and bloated feelings. ...